Mepolizumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Mepolizumab: From Severe Eosinophilic Asthma to Immune Thrombocytopenia
One-Sentence Summary
Mepolizumab is a humanized anti-interleukin-5 (IL-5) monoclonal antibody, established for treating eosinophil-driven conditions such as severe eosinophilic asthma. The TxGNN model predicts it may be effective for immune-mediated thrombocytopenia (thrombocytopenia due to immune destruction), but currently only 1 case report supports this direction, with no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Severe eosinophilic asthma (anti-IL-5 antibody class; TFDA/TGA-specific approved indication text not available in this evidence pack) |
| Predicted New Indication | Thrombocytopenia due to immune destruction |
| TxGNN Prediction Score | 99.66% |
| Evidence Level | L4 (single case report only; no clinical trials) |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack for Mepolizumab. Based on known information, Mepolizumab belongs to the anti-IL-5 monoclonal antibody class, and its efficacy in eosinophil-driven respiratory and haematological conditions has been established; mechanistically it may be applicable to immune-mediated thrombocytopenia where eosinophilic or immune-complex-driven inflammatory activity contributes to platelet destruction.
The single available piece of literature evidence (PMID 28648630) describes resolution of a steroid-resistant hypereosinophilic condition with concomitant thrombotic microangiopathy following mepolizumab treatment, suggesting a plausible immunomodulatory link between eosinophil suppression and improvement in platelet-related pathology. However, this is anecdotal, single-patient evidence rather than a systematic evaluation of mepolizumab in immune thrombocytopenia specifically, so the mechanistic rationale remains preliminary.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28648630 | 2018 | Case report | Blood Cells, Molecules & Diseases | Resolution of a steroid-resistant hypereosinophilic condition and concomitant thrombotic microangiopathy following mepolizumab treatment in a patient with atypical HUS-associated eosinophilia |
Australia Market Information
Mepolizumab is not currently registered on the ARTG (0 entries) and has no marketed status in Australia in this evidence pack, so no product-level dosage form or approved indication text can be listed.
Safety Considerations
As Mepolizumab is not currently marketed in Australia, no TGA-approved Product Information is available locally. Once available (e.g. following TGA registration or via overseas-approved PI), key warnings, contraindications, and drug interaction data should be reviewed before any clinical use is considered.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for the predicted indication rests on a single anecdotal case report with no registered clinical trials, and Mepolizumab is not currently marketed or registered in Australia — insufficient to progress past initial screening.
To proceed, the following is needed:
- TFDA/TGA-approved Product Information (warnings, contraindications) — currently a blocking data gap
- Confirmed mechanism of action data from DrugBank or product labelling
- Broader literature/trial search using synonymous terms (e.g. “immune thrombocytopenic purpura”, “ITP”) since the current search used a narrow ontology term that may have missed relevant studies
- Confirmation of original approved indication(s) and any existing ARTG/TGA submission status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.